ABSTRACT
The target-specific oral anticoagulants (TSOACs), eg, dabigatran, rivaroxaban, and apixaban, are changing the way we manage thromboembolic disease. At the same time, many clinicians wonder how best to manage TSOAC therapy when patients need surgery. An in-depth understanding of these drugs is essential to minimize the risk of bleeding and thrombosis perioperatively.
Footnotes
↵* Dr. Trujillo has disclosed consulting for Boehringer Ingelheim, Janssen Pharmaceuticals, and Pfizer/Bristol-Myers Squibb.
- Copyright © 2014 The Cleveland Clinic Foundation. All Rights Reserved.
View Abstract
